Skip to content
For research use only. Not for human or veterinary use. Not a drug, food, or dietary supplement.
AMIRAVOResearch Library
Cycle-length evidence

CJC-1295 (no DAC) + GHRP-6 Blend cycle length: what human studies ran

Not approved — research use only
Short answer: there is no established CJC-1295 (no DAC) + GHRP-6 Blend cycle length, and we found no human studies that report one.

Treatment and follow-up in human studies

No human study durations are recorded.

What has not been tested

  • On-and-off schedules or breaks between courses.
  • Repeated courses and long-term exposure beyond the periods listed.
  • CJC-1295 (no DAC) + GHRP-6 Blend combined with other compounds, unless a study above says so.

Frequently asked questions

Is there an established CJC-1295 (no DAC) + GHRP-6 Blend cycle length?
No. We found no human studies that report a treatment duration for CJC-1295 (no DAC) + GHRP-6 Blend.
What is the longest human study of CJC-1295 (no DAC) + GHRP-6 Blend?
None is recorded.
Do study durations tell me how long to use something?
No. A study duration is how long investigators administered a compound to selected participants under monitoring. It is not a recommended course, and a break between courses has not been tested for any compound on this site that is not approved.
CJC-1295 (no DAC) + GHRP-6 Blend dosing reference Full research page

References

  1. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults J Clin Endocrinol Metab. 2006
  2. Use of growth-hormone-releasing peptide-6 (GHRP-6) for the prevention of multiple organ failure Clin Sci (Lond). 2006
  3. The emerging landscape of performance-enhancing peptides modulating GH-IGF1 axis: bridging the gap between clinical evidence and patient self-administration Front Endocrinol (Lausanne). 2026
  4. Peptides in urology and sexual medicine: clinical effectiveness, dosing, indications, and safety: a narrative review Sex Med Rev. 2026
  5. Bulk Drug Substances Nominated for Use in Compounding Under Section 503A of the Federal Food, Drug, and Cosmetic Act (updated May 14, 2026) FDA. 2026
  6. PubMed search: "CJC-1295" AND "GHRP-6" (3 records, none an experiment on the combination; searched 22 October 2026) PubMed. 2026
  7. World Anti-Doping Code International Standard: Prohibited List 2026 WADA. 2026
  8. Doping control analysis of seven bioactive peptides in horse plasma by liquid chromatography-mass spectrometry Anal Bioanal Chem. 2013
  9. Dangers of Injectable Peptides and Other Unregulated "Biohacking" Drugs Mo Med. 2026